SEC Form 4 · accession 0000899243-18-020458

CONSTELLATION PHARMACEUTICALS INC · CNST

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jul 23, 2018

Accepted (ET)

Jul 23, 2018 · 8:15 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001434418

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 23, 2018	C	2,164,073	—	A	2,164,073	D
Common Stock	Jul 23, 2018	P	133,333	$15.00	A	2,297,406	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series E Preferred Stock^F1	—	Jul 23, 2018	C	6,666,666	D	—	—	Common Stock	778,583	D
Series E-1 Preferred Stock^F1	—	Jul 23, 2018	C	6,502,856	D	—	—	Common Stock	590,684	D
Series F Preferred Stock^F1	—	Jul 23, 2018	C	8,750,000	D	—	—	Common Stock	794,806	D

F1On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.